Environmental radioactivity in the Netherlands : Results in 2017 RIVM reports annually on the level of radioactivity that occurs under normal circumstances in the environment and food.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
WHO:RIVM Centre for Healthy Living a good practice for other countries According to the World Health Organization (WHO), the RIVM Centre for Healthy Living is a prime example of how the national government has taken up its stewardship role within the health promo
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
New standard for exposure assessment of cleaning products RIVM has updated the standard for exposure assessment of cleaning products in the ConsExpo Cleaning Products Fact Sheet.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
RIVM launches new web-based version of ConsExpo An improved version of the computer program ConsExpo is now available via the RIVM website.
Integrated approach reduces harmful effects of medicines in surface waters Residues of medicinal products, such as painkillers, hormones and antidepressants, are increasingly detected in surface water and drinking water.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.